Egyptian Society of AndrologyHuman Andrology2090-60487320170901Evaluation of the Sildenafil Effect on Female Sexual Dysfunction8491524810.21608/ha.2017.1201.1008ENAbdallaKandilDermatology,Venereology& Andrology department, Faculty of Medicine, Zagazig UniversityElsayed M.GalalDepartment of Dermatology,Venereology & Andrology, Faculty of Medicine, Zagazig University, Zagazig, EgyptAmina M.ShawqyDepartment of Dermatology,Venereology & Andrology, Faculty of Medicine, Zagazig University, Zagazig, EgyptJournal Article20170617Background : Female Sexual Dysfunction (FSD) is a disturbance or dysfunction in the process of desire, arousal or orgasm which can be a symptom of a biological condition, a psychological problem or an interpersonal issue or a combination of these factors. Female Sexual Dysfunction is a multi-causal and a multi-dimensional medical problem that adversely affects physical health & emotional wellbeing. Also impaired sexual function has damaging effects on the self esteem, sense of wholeness and interpersonal relationships of women. It is often emotionally distressing and might lead to familial discord and divorce, and reproduction is also affected. Sildenafil is selective type 5 phosphodiesterase (PDE5) inhibitors , taken orally and effective for men with erectile dysfunction. Previous studies suggested that sildenafil, which acts by inhibiting cyclic GMP specific PDE5, may improve the sexual health of women affected by sexual difficulties such as arousal disorders and may indirectly improve other aspects of sexual life. Sildenafil was effective and well tolerated in post menopausal women with sexual arousal disorder without concomitant hypoactive sexual desire disorder or contributory emotional relationship or historical abuse issues. Objective: This study aims to evaluate the effect of sildenafil citrate on female sexual dysfunction. Subjects and Methods: The study was conducted in Dermatology,Venereology, and Andrology department, Faculty of Medicine, Zagazig University Hospitals during the period from April 2015 to August 2016. Twenty six married female patients were included in this study. Patients were divided into two groups. Group 1 contains thirteen patients took 50mg sildenafil on demand and group 2 contains thirteen patients took placebo. Results: There was no significant differences between the studied groups regarding the demographic data, and FSFI scors. There was significant differences between pre and post treatment of sexual dysfunction scors regarding group І. There was no significant differences in post treatment results between the two studied groups as regard sexual dysfunction except in orgasm and pain. Conclusions: Sildenafil citrate may be effective in women who couldn’t achieve orgasm and decrease pain in patients with dysparunia.https://ha.journals.ekb.eg/article_5248_887cbb4866b1fef3279f2d6b8916a1fb.pdfEgyptian Society of AndrologyHuman Andrology2090-60487320170901Evaluation of Erectile Function and Mood Changes among Male Patients with Hansen's disease9297524910.21608/ha.2017.3956ENAhmed A.MoussaDepartment of Andrology, Sexology and S.T.Ds, Faculty of Medicine, Beni-Suef University, Beni-Suef, EgyptHany H.DessokiDepartment of psychiatry, Faculty of Medicine, Beni-Suef University, Beni-Suef, EgyptGhada A.AhmedDepartment of Dermatology and Venereology Faculty of Medicine, Beni-Suef University, Beni-Suef, EgyptMohamed Abdel FatahFarag4Lecturer of Andrology & S.T.Ds. Faculty of Medicine Cairo University, Cairo, EgyptJournal Article20160818Purpose: To evaluate evaluation of the erectile function and mood changes in male patients with Hansen’s disease (HD).<br />Methods: this study was conducted on fForty males (40) confirmed patients with Hansen's disease were enrolled in this research., theAll patients were subjected to the underwent the following: full Hhistory taking, International index of erectile function (IIEF-5), Beck anxiety scale and Beck depression scale.<br />Results: About 77.5% of our patients had erectile dysfunction, and 87.5% of patients showed anxiety disorders. while While 52.5% of patients showed depressive disorders and, 27.5% of patients had abnormal free testosterone levels. There was A high negative significant correlation revealed between IIEF-5 score and deformity grading, but with there was no significant association between duration or type of leprosy and psychiatric disorders. The results showed significant negative correlation between IIEF-5 and Beck depression inventory. But no statistical significant difference regarding free testosterone level (p-value=0.109) was found between erectile dysfunction (ED) group and non ED group.<br />Conclusion: Erectile dysfunction, anxiety and depression are very common in among patients with Hansen's disease. and sSuch problems are related to level of deformity not to type or duration of disease and not related to testosterone level. This finding could be of key importance for the clinical practice because it could modify the current management of patients with Hansen's disease.https://ha.journals.ekb.eg/article_5249_a1cc12a9c95d68b3a2173e0ddb09f274.pdfEgyptian Society of AndrologyHuman Andrology2090-60487320170901YKL-40: An Emerging Biomarker of Endothelial Dysfunction in Arteriogenic Erectile Dysfunction98104525010.21608/ha.2017.904.1001ENHanan HassanSabryDermatology, Venereology and Andrology, Benha Faculty of medicine , Benha University,EgyptAhmed H.HamedDepartments of Dermatology Venereology and Andrology, Faculty of Medicine, Benha University, Benha, EgyptJehan H.SabryClinical and chemical Pathology, Faculty of Medicine, Benha University, Benha, EgyptOsama H.Abdel-SalamaDepartments of Dermatology Venereology and Andrology, Faculty of Medicine, Benha University, Benha, EgyptJournal Article20170411Introduction: Endothelial dysfunction is a central etiologic factor in the development of atherosclerosis and systemic vascular disease, which includes erectile dysfunction. YKL-40 has been suggested to be a new marker of inflammation, atherosclerosis, and endothelial dysfunction. Aim: To estimate serum levels of YKL40, as a new serum marker of endothelial dysfunction, in patients with arteriogenic erectile dysfunction. Patients and Methods: Hundred subjects including 50 with arteriogenic erectile dysfunction and 50 healthy as a control group were enrolled to the study. Serum YKL-40 levels were measured in patients and controls using ELISA technique. Results: Serum YKL-40 levels was significantly elevated in arteriogenic ED patients compared with controls. Positive significant correlations were found between serum levels of YKL40 and patients’ age (r=0.588, p=0.001), duration of erectile dysfunction (r=0.673, p=0.001), BMI (r=0.598, p=0.001). The patients with hypertension had significantly elevated YKL-40 levels than those who were normotensive (164.88 ± 191.73 Vs 60.22 ± 26.44, respectively).<br />Conclusion: Serum levels of YKL-40 are elevated in arteriogenic ED patients denoting that endothelial dysfunction play a role in the pathogenesis of arteriogenic ED and YKL-40 as a novel marker of endothelial dysfunction could be a marker of arteriogenic erectile dysfunction.https://ha.journals.ekb.eg/article_5250_5fdfdaad54d5343db5c40546b4e5ac0a.pdfEgyptian Society of AndrologyHuman Andrology2090-60487320170901Study of the Role of Body Mass Index and Serum Leptin as Potential Risk Factors in Patients with Lifelong Premature Ejaculation105110525110.21608/ha.2017.1571.1013ENTarekTawfikDepartment of Dermatology & STDs Al-Azhar UniversityMohamedArefChemical Pathology Al-Azhar University
Al-Azhar UniversitySamehGamalEl DinDepartment of Andrology & STDs, Cairo UniversityMohamedAbd El Mawgood4Department of Dermatology & STDs Al-Azhar UniversityAhmedKhattabDepartment of Dermatology & STDs Al-Azhar UniversityJournal Article20170827Introduction: several studies demonstrated the potential role of serum leptin in patients with premature ejaculation.<br />Aim: we aimed in this study to evaluate the correlation between body mass index, serum leptin and intra-vaginal ejaculation latency time in patients with lifelong premature ejaculation and healthy controls.<br />Patients and Methods: this study was carried out on 80 consecutive patients and controls. Body mass index was measured in the patients and the controls. Serum leptin was measured in both groups at the end of the study. Additionally, the patients and the controls were asked to measure intra vaginal ejaculation latency time (IELT) by stop watch handled by their wives for 2 successive months.<br />Results: our prospective analysis revealed a highly significant association between body mass index and serum leptin and intra-vaginal ejaculation latency time among the cases (p-value < 0.001, Discussion: the current study demonstrated a statistically significant association between BMI and serum leptin and IELT in the patients with lifelong premature ejaculation. Additionally, the results revealed a statistically significant association between BMI and IELT in the controls without any association with the serum leptin.<br />Conclusion: the current study highlights the role of both body mass index and serum leptin as potential risk factors in patients with lifelong premature ejaculation. Eventually, future studies are required to duplicate this interesting association between body mass index, serum leptin and intra-vaginal ejaculation latency time in patients with lifelong premature ejaculation.https://ha.journals.ekb.eg/article_5251_b8f4cfb7ef363351703e936a759c0741.pdf